Physician profile
Dpinder Singh
NPI 1659488617
$12,593.53
in general payments reported to CMS, 2019-2025
45 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $2,039 · 2021: $2,389 · 2022: $1,876 · 2023: $1,502 · 2024: $1,552 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,542 · Education: $11.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,542.37 |
| Education | $11.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,522.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,458.66 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,407.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,199.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,087.29 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Pfizer INC. | $714.62 | 2019-2025 | |
| Amgen INC. | $668.89 | 2019-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $590.45 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $450.32 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $326.18 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $304.50 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $273.16 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $250.97 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.41 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.61 | 2020-2025 | Xifaxan, Trulance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dpinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.